Immunomodulators in chronic lymphocytic leukemia: Where does lenalidomide belong?

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1382-1385

  Brown, Jennifer R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

CLL; lenalidomide; tumor flare

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIALYSIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; LEUKOCYTOSIS; LOW DRUG DOSE; LYMPH NODE PAIN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; SHORT SURVEY; SKIN TOXICITY; SWELLING; THROMBOSIS; TREATMENT RESPONSE; TUMOR FLARE; TUMOR LYSIS SYNDROME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; THALIDOMIDE;

EID: 77955436262     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.496017     Document Type: Short Survey

References (18)

1. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349.
2. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111: 5291-5297.
3. Chanan-Khan A, Czuczman MS, Padmanabhan S, et al. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. Blood 2007; 110(Suppl. 1): 914A (Abstract 3108).
4. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with highrisk cytogenetics. Leuk Lymphoma 2010;51:85-88.
5. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-2525.
6. Chen CI, Paul H, Xu W, et al. Safety and efficacy of slow dose escalation of lenalidomide for frontline treatment in chronic lymphocytic leukemia (CLL) - results of a phase II study. Haematologica 2009;94:S93.
7. Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047.
8. Maddocks K, Lapalombella R, Blum KA, et al. Preliminary results of a phase I study of lenalidomide in relapsed chronic lymphocytic leukemia. Blood 2009;114(Suppl.1):1339 (Abstract 3446).
9. Wendtner CM, Mahadevan D, Stilgenbauer S, et al. Preliminary results of a phase 1/2, multi-center, open-label study (CLL-001) investigating a stepwise dose-escalation schedule of lenalidomide in relapsed or refractory chronic lymphocytic leukemia. Blood 2008;112(Suppl. 1): 732 (Abstract 2104).
10. Badoux XC, Wierda WG, O'Brien SM, et al. Experience with lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. Haematologica 2009;94:S93.
11. Gao H, Ferrajoli A, Cohen EN, et al. Treatment with lenalidomide has a positive immunomodulatory effect in patients with chronic lymphocytic leukemia. Blood 2008; 112(Suppl. 1): 733 (Abstract 2107).
12. Brown JR, Abramson JS, Hochberg EP, et al. A phase I study of lenalidomide in combination with fludarabine-rituximab in previously untreated CLL/SLL. Blood 2009;114(Suppl. 1): 1330 (Abstract 3426).
13. Brown JR, Abramson JS, Hochberg EP, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Haematologica 2009; 94:S86.
14. Egle A, Steurer M, Melchardt T, Stoll M, Greil R. The REVLIRIT CLL5 AGMT Study - a phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated CLL: results of a planned interim analysis. Blood 2009;114(Suppl. 1): 1341 (Abstract 3453).
15. Ferrajoli A, Badoux XC, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2009;114(Suppl. 1): 89 (Abstract 206).
16. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase dependent pathway. Blood 2010;115:2619-2629.
17. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266-1273.
18. James D, Avery ED, Zhang L, et al. Lenalidomide administered for the initial treatment of CLL patients - in vivo modulation of the leukemia cell surface phenotype and association with tumor flare reaction (TFR). Blood 2009;114(Suppl. 1): 1336 (Abstract 3440).